World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Professor John Axford - Professor of Rheumatology (MD., DSc, F.R.C.P.)

Professor John Axford studied medicine at University College, London in 1989. He was chosen as a Fulbright Scholar and performed research in various areas of immunology both at the Middlesex Hospital Medical School, and Tufts University, USA. In 1990, Professor Axford completed his research thesis in arthritic diseases and in 1991 was awarded his M.D. with a Specialist Accreditation in Rheumatology and Immunology.

He has lectured extensively throughout the United States, the United Kingdom, Europe, Australia, and Asia and has authored or co-authored over 80 published peer-reviewed scientific papers, over 128 published abstracts and letters, and 18 medical textbooks. Professor Axford is a past section President of the Royal Society of Medicine and currently serves on the Editorial Boards of three medical journals and on numerous medical and health related committees. He is also Editor of the Undergraduate textbook 'Medicine'.

At present, Professor Axford is the Professor of Clinical Rheumatology and the Director of Sir Joseph Hotung Centre for Musculoskeletal Disorders for St George's University of London, where he directs the provision of clinical and basic scientific research, clinical care and both undergraduate and postgraduate education. He joined St George's University of London in 1990 and was appointed Chair of Clinical Rheumatology in 2005.

Currently, Professor Axford is serving as the Principal Investigator for 2 three-year clinical trials funded by St. George's University of London and NHS Hospital.

Back to experts

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more